X4 Pharmaceuticals, Inc (XFOR) Balance Sheet
As of 2026-06-30 (10-Q), X4 Pharmaceuticals, Inc (XFOR) reported total assets of $253.1M, total liabilities of $97.6M and shareholders' equity of $155.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $195.1M. Long-term debt: $75.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XFORX4 Pharmaceuticals, IncFollow XFOR — free
—
Price chart with a free account
- Market cap
- 321.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.1 | 126.2 | 78.7 | 81.8 | 121.7 | 99.2 | 55.7 | 217.0 | 195.1 | |
| Receivables | — | 0.0 | — | — | — | 0.0 | 1.1 | 0.6 | 2.0 | |
| Inventory | — | — | — | — | — | 0.0 | 0.7 | 0.6 | 0.4 | |
| Current assets | 9.3 | 129.3 | 83.3 | 87.9 | 128.7 | 122.1 | 112.2 | 261.6 | 218.9 | |
| Total assets | 9.9 | 160.7 | 122.9 | 117.2 | 155.6 | 147.3 | 146.4 | 290.5 | 253.1 | |
| Current liabilities | 7.9 | 9.4 | 11.9 | 14.0 | 22.3 | 22.9 | 32.9 | 25.8 | 19.4 | |
| Long-term debt | 10.0 | 20.0 | 32.5 | 32.5 | 32.5 | 55.0 | 75.0 | 75.0 | 75.0 | |
| Short-term debt | 1.7 | 0.0 | 0.0 | 0.8 | 1.3 | 0.0 | — | — | — | |
| Total liabilities | 21.6 | 31.5 | 50.1 | 52.8 | 81.5 | 96.2 | 124.3 | 104.2 | 97.6 | |
| Shareholders' equity | -77.1 | 129.2 | 72.8 | 64.4 | 74.1 | 51.1 | 22.1 | 186.3 | 155.5 |
USD millions · SEC XBRL
X4 Pharmaceuticals, Inc — questions
- How much cash does X4 Pharmaceuticals, Inc have?
- $195.1M in cash and cash equivalents as of 2026-06-30.
- How much debt does X4 Pharmaceuticals, Inc have?
- $75.0M of long-term debt as of 2026-06-30.
- What are X4 Pharmaceuticals, Inc's total assets?
- $253.1M as of 2026-06-30.
- What is X4 Pharmaceuticals, Inc's shareholders' equity?
- $155.5M as of 2026-06-30.
Every figure on this page comes from X4 Pharmaceuticals, Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.